PKI 14-22 amide,myristoylated

PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs^[1][2][3]. In Vitro:PKI 14-22 amide,myristoylated (20-40 μM; 72 h) significantly inhibits Zika virus replication in HUVEC and astrocytes, reducing viral titers by more than 85% without causing significant cytotoxicity^[2].
PKI 14-22 amide,myristoylated (10-40 μM; 4-24 h) inhibits viral structural protein (capsid/NS1) expression and positive and negative strand RNA synthesis^[2]. In Vivo:PKI 14-22 amide, myristoylated (5 nmol/mouse; intracerebroventricular injection; 3 times: 1 time/1 hour before surgery + 2 times/24 and 48 hours after surgery) completely preventes the development of Morphine analgesic tolerance in the mouse morphine tolerance model, without affecting the withdrawal reaction induced by Naloxone (HY-17417A)^[3].